Transcenta Partners with EirGenix for HiCB Platform Licensing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Strategic Collaboration: Transcenta has entered into a non-exclusive licensing agreement with EirGenix, granting access to its Highly Intensified Continuous Bioprocessing (HiCB) platform, which is expected to yield substantial upfront and milestone payments, thereby enhancing long-term value for both companies.
- Technology Sharing: By providing the HiCB platform, Transcenta aims to improve production efficiency and product consistency in biopharmaceutical manufacturing while significantly reducing costs, ultimately expanding global patient access to high-quality biologics.
- Market Expansion: EirGenix plans to utilize the HiCB platform to support its biologics development and manufacturing, catering to CDMO clients seeking intensified and continuous manufacturing solutions, thereby solidifying its market position in the biopharmaceutical sector.
- Innovation-Driven: Transcenta's CEO emphasized that this collaboration will enhance the affordability and global accessibility of biologics, with future proceeds reinvested to strengthen the technology platform and advance the R&D pipeline for next-generation therapeutics.
06628
$2.31+Infinity%1D
Analyst Views on 06628
Wall Street analysts forecast 06628 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 06628 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 2.170
Low
Averages
High
Current: 2.170
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
